Skip to main content

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease

Objective

CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/clinical medicine/oncology/leukemia

Call for proposal

H2020-SC1-2017-Two-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Address
Josef-schneider-strasse 2
97080 Wurzburg
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 021 250

Participants (9)

OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 893 125
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSIDAD DE NAVARRA
Spain
EU contribution
€ 624 375
Address
Campus Universitario Edificio Central
31080 Pamplona
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
France
EU contribution
€ 384 375
Address
Avenue Oscar Lambret 2
59037 Lille
Activity type
Higher or Secondary Education Establishments
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Germany
EU contribution
€ 342 875
Address
Paul-ehrlich-strasse 51-59
63225 Langen
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH
Germany
EU contribution
€ 685 000
Address
Friedrich Ebert Strasse 107
68167 Mannheim
Activity type
Research Organisations
MYELOMA PATIENTS EUROPE AISBL
Belgium
EU contribution
€ 115 625
Address
Avenue Louise 149 24
1050 Bruxelles
Activity type
Other
NBE-THERAPEUTICS AG
Switzerland
EU contribution
€ 200 000
Address
Hochbergerstrasse 60C Technologie Park Basel
4057 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
T-CURX GMBH
Germany
EU contribution
€ 503 750
Address
Friedrich-bergius-ring 15
97076 Wurzburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ARTTIC
France
EU contribution
€ 327 500
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)